At the time of writing, Heron Therapeutics Inc [HRTX] stock is trading at $2.06, up 1.98%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HRTX shares have gain 10.16% over the last week, with a monthly amount glided 4.04%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on June 13, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $7. Previously, CapitalOne started tracking the stock with Overweight rating on April 23, 2024, and set its price target to $6. On March 13, 2024, Needham reiterated its Buy rating and revised its price target to $5 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $24 on May 27, 2020. Needham reiterated its recommendation of a Buy and reduced its price target to $48 on February 20, 2020. Needham reiterated a Buy rating for this stock on January 16, 2019, and downed its price target to $64. In a note dated April 05, 2018, Evercore ISI initiated an Outperform rating and provided a target price of $56 on this stock.
For the past year, the stock price of Heron Therapeutics Inc fluctuated between $0.50 and $3.93. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $2.06 at the most recent close of the market. An investor can expect a potential return of 239.81% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
According to Heron Therapeutics Inc [NASDAQ:HRTX], the company’s sales were 136.36M for trailing twelve months, which represents an 13.42% jump. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is 1.44 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.97 points at the first support level, and at 1.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.10, and for the 2nd resistance point, it is at 2.15.
Ratios To Look Out For
It is important to note that Heron Therapeutics Inc [NASDAQ:HRTX] has a current ratio of 2.38. Also, the Quick Ratio is 1.85, while the Cash Ratio stands at 0.23. Considering the valuation of this stock, the price to sales ratio is 2.29.
Transactions by insiders
Recent insider trading involved Forbes William P, EVP, Chief Development Officer, that happened on Nov 17 ’23 when 25000.0 shares were purchased. EVP, Chief Development Officer, Forbes William P completed a deal on Nov 16 ’23 to buy 50000.0 shares. Meanwhile, Chief Executive Officer Collard Craig A bought 0.15 million shares on Nov 16 ’23.
